Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease

Digestion

Volumn 85, Issue 1, 2012, Pages 47-54

  Beigel, Florian ^a   Löhr, Beate ^a   Laubender, Rüdiger P ^b   Tillack, Cornelia ^a   Schnitzler, Fabian ^a   Breiteneicher, Simone ^a   Weidinger, Maria ^a   Göke, Burkhard ^a   Seiderer, Julia ^a   Ochsenkühn, Thomas ^a   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anemia; Anemia of chronic disease; Crohn's disease; Ferric carboxymaltose; Ferritin; Inflammatory bowel disease; Iron deficiency; Iron supplementation; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; IRON; LIVER ENZYME; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TOXICITY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; COHORT STUDIES; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; IRON; MALE; MALTOSE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83455164989     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000333091     Document Type: Article

References (37)

1. Wilson A, Reyes E, Ofman J: Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116(suppl 7A):44S-49S.
2. Gasche C, Lomer MC, Cavill I, Weiss G: Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-1197. (Pubitemid 38961976)
3. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276. (Pubitemid 39069926)
4. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788. (Pubitemid 36917762)
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093. (Pubitemid 40007660)
6. Fleming MD: The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008; 151-158.
7. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J: Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-2509.
8. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T: Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-1065. (Pubitemid 41291355)
9. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607.
10. Srigiridhar K, Nair KM, Subramanian R, Singotamu L: Oral repletion of iron induces free radical mediated alterations in the gastrointestinal tract of rat. Mol Cell Biochem 2001; 219: 91-98. (Pubitemid 32331449)
11. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP: Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001; 15: 1989-1999. (Pubitemid 34014356)
12. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK: Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003; 38: 543-548. (Pubitemid 36609862)
13. De Silva AD, Tsironi E, Feakins RM, Rampton DS: Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005; 22: 1097-1105. (Pubitemid 41779517)
14. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C: A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (Ferinject *) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192. (Pubitemid 351677967)
15. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A: Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267-278. (Pubitemid 47356650)
16. Breymann C, Gliga F, Bejenariu C, Strizhova N: Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73.
17. Tagboto S, Cropper L, Turner J, Pugh-Clarke K: The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject ® ) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care 2009; 35: 18-23.
18. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P: Rationale and design of Ferinject ®assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009; 11: 1084-1091.
19. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
20. Qunibi WY: The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399-412.
21. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C: FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-853.e1-2.
22. Wilson A, Yu HT, Goodnough LT, Nissenson AR: Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004; 116(suppl 7A):50S-57S.
23. Gasche C: Complications of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 49-56. (Pubitemid 30085389)
24. Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, Howell JB, Infantolino A, Dimarino AJ, Cohen S: Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 47-52. (Pubitemid 43032451)
25. Wells CW, Lewis S, Barton JR, Corbett S: Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123-130.
26. Stein J, Hartmann F, Dignass AU: Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599-610.
27. Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, Kisling S, Schuemann K, Haller D: Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease- like ileitis. Gut 2011; 60: 325-333.
28. Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell JJ: Intake of dietary iron is low in patients with Crohn's disease: a case-control study. Br J Nutr 2004; 91: 141-148. (Pubitemid 38111121)
29. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, Nemeth E, Grand RJ, Weinstein DA: Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006; 12: 1101-1106. (Pubitemid 44847466)
30. Kociol RD, Newby LK: Ferric carboxymaltose improved symptoms and quality of life in patients with chronic heart failure and iron deficiency. Ann Intern Med 2010; 152:JC4-JC5.
31. Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE: Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant 2010; 25: 2368-2375.
32. Schaefer RM, Khasabov NN, Todorov NG, et al: The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association, Stockholm, May 10-13, 2008, abstract Mp375.
33. Qunibi M: Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose intravenous iron, across ten multi-center clinical trials. 40th Annual Meeting of the American Society of Nephrology, San Francisco, November 2-5, 2007, poster abstract.
34. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.
35. Fleming RE, Sly WS: Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001; 98: 8160-8162. (Pubitemid 32678004)
36. Katsanos K, Cavalier E, Ferrante M, Van Hauwaert V, Henckaerts L, Schnitzler F, Katsaraki A, Noman M, Vermeire S, Tsianos EV, Rutgeerts P, Chapelle JP, Van Assche G: Intravenous iron therapy restores functional iron deficiency induced by infliximab. J Crohns Colitis 2007; 1: 97-105. (Pubitemid 350265736)
37. Domenech E, Manosa M, Masnou H, Navarro M, Garcia-Planella E, Bernal I, Gassull MA: Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 2005; 100: 496. (Pubitemid 40314539)